The Coronavirus disease 2019 (COVID‐19) outbreak has led to a pandemic with an overwhelming impact on daily living and the health care system. Major life‐threatening complications may occur [1]. Although most patients suffer from respiratory symptoms, different neurological symptoms have been described, either directly or indirectly caused by COVID‐19 [2]. Within the movement disorder spectrum, myoclonus has been observed as a COVID‐19‐related feature in several patients [3‐5].

Apathy is a neurobehavioural symptom affecting Parkinson’s disease patients of all disease stages. Apathy seems to be associated with a specific underlying non-motor disease subtype and reflects dysfunction of separate neural networks with distinct neurotransmitter systems. Due to the complicated neuropsychiatric aetiology of apathy, clinical assessment of this invalidating non-motor symptom remains challenging. We aim to summarize the current findings on apathy in Parkinson’s disease and highlight knowledge gaps. We will discuss the prevalence rates across the different disease stages and suggest screening tools for clinically relevant apathetic symptoms. We will approach the fundamental knowledge on the neural networks implicated in apathy in a practical manner and formulate recommendations on patient-tailored treatment. We will discuss the Park apathy phenotype in detail, shedding light on different clinical manifestations and implications for prognosis. With this review, we strive to distil the vast available theoretical knowledge into a clinical and patient-oriented perspective.